VXRT - Vaxart, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.7000
-0.1800 (-4.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.8800
Open3.8900
Bid0.0000 x 1300
Ask0.0000 x 1100
Day's Range3.6000 - 3.9878
52 Week Range2.3700 - 11.8800
Volume167,930
Avg. Volume366,600
Market Cap26.422M
Beta (3Y Monthly)0.29
PE Ratio (TTM)N/A
EPS (TTM)-4.1310
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-09
1y Target Est5.00
Trade prices are not sourced from all markets
  • InvestorPlace7 days ago

    Vaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain

    Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.

  • Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
    Zacks11 days ago

    Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

    Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

  • ACCESSWIRE11 days ago

    Today’s Research Reports on Stocks to Watch: Guardant Health and Vaxart

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.

  • MarketWatch12 days ago

    Vaxart's stock soars after upbeat results from oral flu vaccine trial

    Shares of Vaxart Inc. shot up 44% in premarket trade Thursday, after the biotechnology company announced results from a phase 2 trial that its oral flu vaccine performed better than Sanofi's Fluzone. Sanofi's U.S.-listed shares shed 1.6% ahead of the open. "These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%," said Chief Scientific Officer Sean Tucker. Wouter Latour, chief executive of Vaxart, said, "We believe this clearly differentiates our oral vaccines from conventional injectable vaccines, and strongly suggests that vaccines based on Vaxart's proprietary vector adjuvant system could be optimal to protect against mucosal pathogens, including some of the major public health threats such as flu, norovirus, RSV and many others." The stock has tumbled 55.4% year to date through Wednesday, while the iShares Nasdaq Biotechnology ETF has rallied 13.6% and the S&P 500 has gained 9.4%.

  • Business Wire12 days ago

    New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018. “These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%.

  • Business Wire2 months ago

    Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.

  • Business Wire3 months ago

    Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus oral tablet vaccine in the Journal of Clinical Investigation Insight. The paper by Leesun, Kim, et al., “Safety and immunogenicity of an oral tablet norovirus vaccine, a phase 1 randomized, placebo-controlled trial”, highlights the benign safety profile of the Vaxart vaccine and describes the generation of robust systemic and mucosal immune responses, including mucosal IgA, memory B cells, and serum blocking antibody titers (BT50), all potential correlates of protection.

  • Business Wire4 months ago

    Oral RSV Vaccine - Preclinical Data Published in Vaccine

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral F-protein based Respiratory Syncytial Virus (RSV-F) vaccine. The findings were published in the most recent online version of Vaccine (Joyce C. et al., “Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats”). As described in the article, the oral RSV-F vaccine candidate provided complete sterilizing protection against RSV infection in the cotton rat challenge model at the target dose.

  • Business Wire4 months ago

    Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel dosed topically twice daily in 218 subjects for the treatment of condyloma, or anogenital warts. The primary efficacy endpoint was defined as complete clearance of baseline condyloma by week 16.

  • Business Wire5 months ago

    Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018, at 1:00 p.m. EST in New York. A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.

  • Business Wire5 months ago

    Vaxart to Present at ASM Microbe 2018

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.

  • Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?
    Simply Wall St.5 months ago

    Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?

    Measuring Vaxart Inc’s (NASDAQ:VXRT) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • Business Wire5 months ago

    Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2018 and provided a corporate update.

  • Business Wire6 months ago

    Vaxart Appoints Dr. David Taylor as Chief Medical Officer

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor, M.D., as Chief Medical Officer.

  • Business Wire6 months ago

    Vaxart Announces $5 Million Inavir® Revenue Milestone

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir®, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone ...

  • Business Wire6 months ago

    Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President, Commercial Operations.

  • Business Wire6 months ago

    Vaxart to Present at Two Upcoming Medical Meetings

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya virus study will be highlighted in an oral presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases , taking place from April 21-24, 2018 in Madrid, ...

  • Business Wire6 months ago

    Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress , taking place from April 2-5, 2018 in Washington, D.C.

  • Who Really Owns Vaxart Inc (NASDAQ:VXRT)?
    Simply Wall St.7 months ago

    Who Really Owns Vaxart Inc (NASDAQ:VXRT)?

    Today, I will be analyzing Vaxart Inc’s (NASDAQ:VXRT) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affect shareRead More...

  • Business Wire7 months ago

    Vaxart to Present at the 17th Annual Needham Healthcare Conference

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the 17th Annual Needham Healthcare Conference on Wednesday, March 28, 2018, at 3:30 p.m.

  • Business Wire7 months ago

    Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance

    Vaxart, Inc. a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Company’s novel manufacturing process for producing hydrazine, a key intermediate in the preparation of teslexivir .

  • Business Wire7 months ago

    Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its norovirus oral tablet vaccine at the upcoming 18th International Congress on Infectious Diseases , taking place from March 1-4, 2018 in Buenos Aires, Argentina.